Serious errors plague DNA tool that’s a workhorse of biology
By Katherine Bourzac,
Nature
| 07. 10. 2024
Image by NOAA Great Lakes Environmental Research from Flickr
Laboratory-made plasmids, a workhorse of modern biology, have problems. Researchers performed a systematic assessment of the circular DNA structures by analysing more than 2,500 plasmids produced in labs and sent to a company that provides services such as packaging the structures inside viruses so they can be used as gene therapies. The team found that nearly half of the plasmids had design flaws, including errors in sequences crucial to expressing a therapeutic gene. The researchers posted their findings to the preprint server bioRxiv last month ahead of peer review1.
The study shines a light on “a lack of knowledge” about how to do proper quality control on plasmids in the lab, says Hiroyuki Nakai, a geneticist at Oregon Health & Science University in Portland who was not involved in the work. He was already aware of problems with lab-made plasmids, but was surprised by the frequency of errors...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...
